Vuppalanchi, Raj
Noureddin, Mazen
Alkhouri, Naim
Sanyal, Arun J. http://orcid.org/0000-0001-8682-5748
Article History
Accepted: 21 December 2020
First Online: 10 February 2021
Competing interests
: R.V. has received consulting fees for serving on the Data Safety Monitoring Boards for Covance, Enyio and Enanta; R.V. also received research grant support from Gilead Sciences, Zydus Discovery, Cara Therapeutics, Novo Nordisk, Eli Lilly, Astra Zeneca, Terns Pharmaceuticals and Intercept where his institution receives the funding; M.N. has been on the advisory board or a speaker for Allergan, Gilead, Intercept, Pfizer, Novartis, Blade, EchoSens North America, OWL, Simply Speaking and Abbott; M.N. has received research support from Allergan, BMS, Gilead, Galmed, Galectin, Genfit, Conatus, Enanta, Novartis, Shire and Zydus; M.N. is a minor shareholder or has stocks in Anaetos and Viking. N.A. has received research funding from Albireo, Akero, Allergan, Boehringer Ingelheim, Bristol-Myers Squibb, Galmed, Genfit, Gilead, Intercept, Madrigal, MedImmune, Novartis, Novo Nordisk, Pfizer, Poxel and Zydus, and has acted as a speaker for AbbVie, Alexion, Allergan, Eisai, Exelixis, Gilead, Intercept and Salix and as a consultant for Allergan, Gilead and Intercept. A.J.S. is President of Sanyal Biotechnology and has stock options in Genfit, Akarna, Tiziana, Indalo, Durect, Exalenz and Hemoshear; A.J.S. has served as a consultant to AstraZeneca, Nitto Denko, Ardelyx, Conatus, Nimbus, Amarin, Salix, Tobira, Takeda, Fibrogen, Jannsen, Gilead, Lilly, Poxel, Artham, Cymabay, Boehringer Ingelheim, Novo Nordisk, Bird Rock Bio, Novartis, Pfizer, Jannsen and Genfit; A.J.S. has been an unpaid consultant to Intercept, Echosens, Immuron, Galectin, Fractyl, Syntlogic, Afimmune, ChemomAb, Nordic Bioscience and Bristol Myers Squibb; his institution has received grant support from Gilead, Salix, Tobira, Bristol Myers, Shire, Intercept, Merck, AstraZeneca, Mallinckrodt, Cumberland and Novartis; A.J.S. receives royalties from Elsevier and UptoDate.